Does the media refer more to DBVT or ELDN?

In the previous week, Eledon Pharmaceuticals had 3 more articles in the media than DBV Technologies. MarketBeat recorded 4 mentions for Eledon Pharmaceuticals and 1 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.00 beat Eledon Pharmaceuticals' score of 0.39 indicating that DBV Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eledon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, ELDN or CRVS?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eledon Pharmaceuticals N/A N/A -$45.62M -$0.77 N/A Corvus Pharmaceuticals N/A N/A -$15.28M -$0.52 N/A

Is ELDN or CRVS more profitable?

Corvus Pharmaceuticals' return on equity of -38.92% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -116.97% -41.91% Corvus Pharmaceuticals N/A -38.92% -35.75%

Does the media prefer ELDN or CRVS?

In the previous week, Eledon Pharmaceuticals had 2 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 4 mentions for Eledon Pharmaceuticals and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.30 beat Eledon Pharmaceuticals' score of 0.39 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELDN or CRON?

In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than Cronos Group. MarketBeat recorded 4 mentions for Eledon Pharmaceuticals and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.71 beat Eledon Pharmaceuticals' score of 0.39 indicating that Cronos Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cronos Group 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELDN or SPRY?

In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 4 mentions for Eledon Pharmaceuticals and 3 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 1.47 beat Eledon Pharmaceuticals' score of 0.39 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Eledon Pharmaceuticals (ELDN) Competitors

$3.93 +0.12 (+3.15%)

Closing price 03:58 PM Eastern

Extended Trading

$4.03 +0.10 (+2.57%)

As of 07:59 PM Eastern

Compare

ELDN vs. CVAC, DBVT, CRVS, CRON, and SPRY

Should you buy Eledon Pharmaceuticals stock or one of its competitors? MarketBeat compares Eledon Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eledon Pharmaceuticals include CureVac (CVAC), DBV Technologies (DBVT), Corvus Pharmaceuticals (CRVS), Cronos Group (CRON), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry.

How does Eledon Pharmaceuticals compare to CureVac?

Eledon Pharmaceuticals (NASDAQ:ELDN) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

In the previous week, Eledon Pharmaceuticals had 4 more articles in the media than CureVac. MarketBeat recorded 4 mentions for Eledon Pharmaceuticals and 0 mentions for CureVac. Eledon Pharmaceuticals' average media sentiment score of 0.39 beat CureVac's score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eledon Pharmaceuticals	Neutral
CureVac	Neutral

CureVac has a net margin of 199.92% compared to Eledon Pharmaceuticals' net margin of 0.00%. CureVac's return on equity of -23.03% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
CureVac	199.92%	-23.03%	-19.09%

Eledon Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CureVac has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Eledon Pharmaceuticals presently has a consensus target price of $9.67, suggesting a potential upside of 145.97%. CureVac has a consensus target price of $5.50, suggesting a potential upside of 18.03%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Eledon Pharmaceuticals is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
CureVac	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

CureVac beats Eledon Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Eledon Pharmaceuticals has lower revenue, but higher earnings than DBV Technologies. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	169.13	-$146.95M	-$4.46	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A

DBV Technologies currently has a consensus target price of $48.50, suggesting a potential upside of 201.06%. Eledon Pharmaceuticals has a consensus target price of $9.67, suggesting a potential upside of 145.97%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts clearly believe DBV Technologies is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 1.1% of DBV Technologies shares are held by insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Eledon Pharmaceuticals had 3 more articles in the media than DBV Technologies. MarketBeat recorded 4 mentions for Eledon Pharmaceuticals and 1 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.00 beat Eledon Pharmaceuticals' score of 0.39 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eledon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eledon Pharmaceuticals has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. Eledon Pharmaceuticals' return on equity of -116.97% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%

DBV Technologies has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Summary

DBV Technologies and Eledon Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Corvus Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

Eledon Pharmaceuticals currently has a consensus target price of $9.67, indicating a potential upside of 145.97%. Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 163.92%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Eledon Pharmaceuticals had 2 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 4 mentions for Eledon Pharmaceuticals and 2 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.30 beat Eledon Pharmaceuticals' score of 0.39 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eledon Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Corvus Pharmaceuticals' return on equity of -38.92% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A

Summary

Corvus Pharmaceuticals beats Eledon Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Cronos Group?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by insiders. Comparatively, 7.8% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than Cronos Group. MarketBeat recorded 4 mentions for Eledon Pharmaceuticals and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.71 beat Eledon Pharmaceuticals' score of 0.39 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cronos Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eledon Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Cronos Group has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

Eledon Pharmaceuticals has a net margin of 0.00% compared to Cronos Group's net margin of -1.14%. Cronos Group's return on equity of -1.26% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Cronos Group	-1.14%	-1.26%	-1.20%

Cronos Group has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Cronos Group	$146.59M	6.87	-$9.45M	$0.01	270.00

Eledon Pharmaceuticals presently has a consensus target price of $9.67, suggesting a potential upside of 145.97%. Cronos Group has a consensus target price of $2.30, suggesting a potential downside of 14.81%. Given Eledon Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Eledon Pharmaceuticals is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Eledon Pharmaceuticals beats Cronos Group on 8 of the 15 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to ARS Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Eledon Pharmaceuticals has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
ARS Pharmaceuticals	$84.28M	12.11	-$171.30M	-$2.01	N/A

Eledon Pharmaceuticals has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Eledon Pharmaceuticals' return on equity of -116.97% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 4 mentions for Eledon Pharmaceuticals and 3 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 1.47 beat Eledon Pharmaceuticals' score of 0.39 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Eledon Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Eledon Pharmaceuticals presently has a consensus price target of $9.67, suggesting a potential upside of 145.97%. ARS Pharmaceuticals has a consensus price target of $28.60, suggesting a potential upside of 178.21%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Eledon Pharmaceuticals and ARS Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get Eledon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELDN vs. The Competition

Export

Metric	Eledon Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$294.09M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-5.10	11.07	21.07	22.20
Price / Sales	N/A	334.82	530.36	110.15
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	2.91	8.29	10.79	6.50
Net Income	-$45.62M	$23.85M	$3.56B	$336.88M
7 Day Performance	12.93%	5.21%	1.67%	-0.22%
1 Month Performance	1.03%	2.19%	0.43%	0.77%
1 Year Performance	51.15%	60.99%	32.84%	31.57%

Eledon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELDN Eledon Pharmaceuticals	1.8513 of 5 stars	$3.93 +3.1%	$9.67 +146.0%	+40.1%	$294.09M	N/A	N/A	10	News Coverage High Trading Volume
CVAC CureVac	N/A	$4.66 flat	$5.50 +18.0%	N/A	$1.05B	$70.74M	6.47	880
DBVT DBV Technologies	3.5361 of 5 stars	$16.71 -7.8%	$48.50 +190.3%	+67.0%	$989.10M	$5.64M	N/A	80	Positive News
CRVS Corvus Pharmaceuticals	3.8375 of 5 stars	$11.74 -1.3%	$33.33 +183.9%	+217.2%	$987.22M	N/A	N/A	30
CRON Cronos Group	1.5352 of 5 stars	$2.61 -1.0%	$2.30 -11.7%	+42.5%	$971.74M	$146.59M	260.76	450	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELDN) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eledon Pharmaceuticals (ELDN) Competitors

ELDN vs. CVAC, DBVT, CRVS, CRON, and SPRY

How does Eledon Pharmaceuticals compare to CureVac?

Summary

How does Eledon Pharmaceuticals compare to DBV Technologies?

Summary

How does Eledon Pharmaceuticals compare to Corvus Pharmaceuticals?

Summary

How does Eledon Pharmaceuticals compare to Cronos Group?

Summary

How does Eledon Pharmaceuticals compare to ARS Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN vs. The Competition

Eledon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eledon Pharmaceuticals (ELDN) Competitors

ELDN vs. CVAC, DBVT, CRVS, CRON, and SPRY

How does Eledon Pharmaceuticals compare to CureVac?

Does the media favor ELDN or CVAC?

Is ELDN or CVAC more profitable?

Which has more risk and volatility, ELDN or CVAC?

Do institutionals & insiders hold more shares of ELDN or CVAC?

Which has preferable earnings & valuation, ELDN or CVAC?

Do analysts recommend ELDN or CVAC?

Summary

How does Eledon Pharmaceuticals compare to DBV Technologies?

Which has higher valuation & earnings, DBVT or ELDN?

Do analysts rate DBVT or ELDN?

Do insiders and institutionals hold more shares of DBVT or ELDN?

Does the media refer more to DBVT or ELDN?

Is DBVT or ELDN more profitable?

Which has more volatility and risk, DBVT or ELDN?

Summary

How does Eledon Pharmaceuticals compare to Corvus Pharmaceuticals?

Do analysts rate ELDN or CRVS?

Does the media prefer ELDN or CRVS?

Which has more risk and volatility, ELDN or CRVS?

Do insiders and institutionals have more ownership in ELDN or CRVS?

Is ELDN or CRVS more profitable?

Which has stronger earnings and valuation, ELDN or CRVS?

Summary

How does Eledon Pharmaceuticals compare to Cronos Group?

Do institutionals and insiders hold more shares of ELDN or CRON?

Does the media prefer ELDN or CRON?

Which has more volatility and risk, ELDN or CRON?

Is ELDN or CRON more profitable?

Which has higher valuation and earnings, ELDN or CRON?

Do analysts recommend ELDN or CRON?

Summary

How does Eledon Pharmaceuticals compare to ARS Pharmaceuticals?

Which has better earnings & valuation, ELDN or SPRY?

Is ELDN or SPRY more profitable?

Does the media prefer ELDN or SPRY?

Do institutionals and insiders hold more shares of ELDN or SPRY?

Which has more risk and volatility, ELDN or SPRY?

Do analysts rate ELDN or SPRY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN vs. The Competition

Eledon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools